Results 261 to 270 of about 3,169,017 (359)

Where, How, and How Much? A Multicenter Cohort Study of the Relationship Across Lupus Decision‐Aid Modality, Place of Administration, Interruption and Viewing Completeness, and Patient‐Reported Outcomes

open access: yesArthritis Care &Research, EarlyView.
Objective We assessed whether shared decision‐making (SDM) and patient acceptability, feasibility, and overall satisfaction with a computerized patient decision aid (PtDA) for patients with systemic lupus erythematosus (SLE) differs by PtDA setting, modality, and the viewing experience. Methods Patients with SLE were invited to view a self‐administered
Jasvinder A. Singh   +20 more
wiley   +1 more source

​Did a Non‐Medical Biosimilar Switching Policy Cause an Increase in Non‐Biologic/Biosimilar Health Care Resource Utilization or Cost in Patients With Inflammatory Arthritis?

open access: yesArthritis Care &Research, EarlyView.
Objective This study aimed to evaluate the impact of a series of policies that mandated switching patients with inflammatory arthritis (IA) from an originator biologic to a biosimilar in British Columbia, Canada, on health care resource use and cost.
HaoHung Dang   +4 more
wiley   +1 more source

Lived and care experiences of chronic musculoskeletal shoulder pain in Australian adults: A qualitative study

open access: yesArthritis Care &Research, Accepted Article.
Objectives Australian evidence on lived and care experiences of chronic musculoskeletal shoulder pain (CMSP), irrespective of disorder classification or disease, is limited. However, such evidence is important for person‐centred care and informing local service pathways and care guidelines or standards.
Sonia Ranelli   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy